A pilot assessor-blinded randomised controlled trial of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy in Parkinson's Disease

Conditions

Parkinson's disease Mental and Behavioural Disorders Parkinson's disease

Scobie S, Jowett S, Lambe T, Patel S, Woolley R, Ives N, Rick C, Smith C, Brady MC, Clarke C, Sackley C.

2021-08-097 citations

Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: a pilot randomised controlled trial (PD COMM pilot).

Sackley CM, Smith CH, Rick CE, Brady MC, Ives N, Patel S, Woolley R, Dowling F, Patel R, Roberts H, Jowett S, Wheatley K, Kelly D, Sands G, Clarke CE, PD COMM Pilot Collaborative Group.

2018-01-1029 citations

10.1186/s40814-017-0222-z

Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM pilot): study protocol for a randomized controlled trial.

Sackley CM, Smith CH, Rick C, Brady MC, Ives N, Patel R, Roberts H, Dowling F, Jowett S, Wheatley K, Patel S, Kelly D, Sands G, Clarke C.

2014-06-0716 citations

10.1186/1745-6215-15-213

Interventions

Patient will be randomised between Standard NHS SLT versus Lee Silverman Voice Training versus no treatment. Patients who recieve therapy should do so within one month of randomisation and have their

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Idiopathic Parkinson?s disease defined by the UK PDS Brain Bank Criteria. These criteria are in standard use throughout the NHS in the UK and were supported by the NICE guidelines. 2. PD patients who have self or carer-reported problems when asked: "Do you have any problems with your speech or voice?" by their physician or PD nurse specialist 3. Male and female participants

Exclusion criteria

Exclusion criteria: 1. Dementia as usually defined clinically by the patient?s physician. From our experience in PD MED, some patients with moderate to severe dementia have difficulty in completing self-assessment forms 2. Evidence of laryngeal pathology including vocal nodules or a history of vocal strain or previous laryngeal surgery within their medical records or from discussions with client, as LSVT is not appropriate for this group 3. Received SLT in the last 2 year 4. The investigator is certain the person will need SLT within 6 months

Design outcomes

Primary

Measure	Time frame
VHI - Voice Handicap Index measured at baseline, 3 months, 6 months & 12 months.	—

Secondary

Measure	Time frame
1. AIDS - Assessment of Intelligibility of Dysarthic Speech measured at baseline, 3 months, 6 months 2. Comprehension Assessment measured at baseline, 3 months, 6 months 3. EQ-5D - Euroqol measured at baseline, 3 months, 6 months & 12 months 4. ICECAP-O measured at baseline, 3 months, 6 months & 12 months 5. LwD - Living with Dysarthia questionnaire measured at baseline, 3 months, 6 months & 12 months 7. Parkinson's Disease Carers' Questionnaire Quality of Life Assessment measured at baseline, 3 months, 6 months & 12 months 8. PDQ-39 - Parkinsons Disease Questionnaire 39 measured at baseline, 3 months, 6 months & 12 months 9. Resource Usage measured at 3 months, 6 months & 12 months 10. Vocal Loudness measured at baseline, 3 months, 6 months 11. V-RQoL - Voice related Quality of Life Scale measured at baseline, 3 months, 6 months & 12 months.	—

Measure

Time frame

1. AIDS - Assessment of Intelligibility of Dysarthic Speech measured at baseline, 3 months, 6 months 2. Comprehension Assessment measured at baseline, 3 months, 6 months 3. EQ-5D - Euroqol measured at baseline, 3 months, 6 months & 12 months 4. ICECAP-O measured at baseline, 3 months, 6 months & 12 months 5. LwD - Living with Dysarthia questionnaire measured at baseline, 3 months, 6 months & 12 months 7. Parkinson's Disease Carers' Questionnaire Quality of Life Assessment measured at baseline, 3 months, 6 months & 12 months 8. PDQ-39 - Parkinsons Disease Questionnaire 39 measured at baseline, 3 months, 6 months & 12 months 9. Resource Usage measured at 3 months, 6 months & 12 months 10. Vocal Loudness measured at baseline, 3 months, 6 months 11. V-RQoL - Voice related Quality of Life Scale measured at baseline, 3 months, 6 months & 12 months.

—

Countries

United Kingdom

Outcome results

None listed